Picture of Theravance Biopharma logo

TBPH Theravance Biopharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+3.87%
3m+3.34%
6m-5.49%
1yr-32.4%
Volume Change (%)
10d/3m-11.65%
Price vs... (%)
52w High-21.01%
50d MA+6.74%
200d MA+4.69%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-13.22%
Return on Equity-22.88%
Operating Margin-69.61%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Theravance Biopharma EPS forecast chart

Profile Summary

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.

Directors

Last Annual
December 31st, 2023
Last Interim
September 30th, 2024
Incorporated
July 1st, 2013
Public Since
May 16th, 2014
No. of Shareholders
43
No. of Employees
99
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
49,174,296

TBPH Share Price Performance

Upcoming Events for TBPH

Theravance Biopharma Inc at Evercore ISI HealthCONx Conference

Q4 2024 Theravance Biopharma Inc Earnings Release

Theravance Biopharma Inc Annual Shareholders Meeting

Q1 2025 Theravance Biopharma Inc Earnings Release

Similar to TBPH

Picture of 111 logo

111

us flag iconNASDAQ Global Market

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

Picture of Avadel Pharmaceuticals logo

Avadel Pharmaceuticals

us flag iconNASDAQ Global Market

FAQ